Application of imatinib mesylate in preparation of drugs for resisting Parkinson's disease (PD)

A technology for imatinib mesylate and Parkinson's disease, which is applied in the field of application of imatinib mesylate in the preparation of anti-Parkinson's disease drugs, and can solve other functions of imatinib mesylate. There is no literature Reporting and other issues

Inactive Publication Date: 2012-04-11
INSITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, there is no literature re

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of imatinib mesylate in preparation of drugs for resisting Parkinson's disease (PD)
  • Application of imatinib mesylate in preparation of drugs for resisting Parkinson's disease (PD)
  • Application of imatinib mesylate in preparation of drugs for resisting Parkinson's disease (PD)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Embodiment 1, imatinib mesylate (STI571) treats Parkinson's disease

[0031] 1. STI571 can significantly improve MPTP-induced motor dysfunction in mice with chronic Parkinson's disease

[0032] Parkinson's disease is mainly due to pathological changes in the cells located in the substantia nigra of the midbrain, the synthesis of dopamine is reduced, and the excitatory effect of acetylcholine is relatively enhanced. Its incidence rate ranks first among neurodegenerative diseases in the elderly. The main behavioral manifestations are slowness and lack of movement, muscle rigidity, resting tremor, and postural instability.

[0033] 1. Modeling

[0034] Eight-week-old c57BL / 6J mice were randomly divided into 3 groups, 10 mice in each group, administered intraperitoneally in the following manner, once a day, for two consecutive weeks. [1] control group: normal saline; [2] MPTP group: MPTP (20mg / kg, dissolved in normal saline); [3] STI571+MPTP group: intraperitoneal inject...

Embodiment 2

[0064] Embodiment 2, mechanism research

[0065] 1. STI571 can significantly improve MPTP-induced loss of dopamine neurons

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of imatinib mesylate in preparation of drugs for resisting Parkinson's disease (PD). The application of imatinib mesylate (STI571) in preparation of drugs for treating neurodegenerative diseases belongs to the protective range of the invention, and the neurodegenerative diseases can be PD. An experiment proves that by continuous administration of the STI571, the dyskinesia induced by MPTP can be obviously improved, and the cognitive dysfunction of mice can be improved. The STI571 can obviously improve the dopaminergic neuron loss induced by the MPTP, can inhibit the rat CA1 and DG (diacylglycerol) region nerve cell apoptosis reaction induced by rotenone, can obviously inhibit the primary substantia nigra neuron apoptosis and Lewy protein expression induced by rotenone, and can inhibit the phosphorylation activation of PKC (Protein Kinase C) and Akt. The STI571 used as a specific inhibitor of c-Ab1 can resist the formation of PD, can improve the behavioral abnormity and cognitive dysfunction of PD, can be used as a new candidate drug for resisting neurodegenerative diseases such as PD and the like, and has favorable application prospects; and the clinical indications of the STI571 are greatly expanded.

Description

technical field [0001] The invention relates to the application of imatinib mesylate in the preparation of medicaments for treating Parkinson's disease. Background technique [0002] Imatinib mesylate (STI571), the chemical name is 4-(4-methyl-1-piperazine)methyl-N-4-methyl-3-4-(3-pyridine)-2-pyrimidine Aminophenyl-aniline mesylate is currently mainly used in the treatment of chronic myelogenous leukemia in foreign countries. STI571 can significantly inhibit the proliferation of leukemia cells, arrest cells in G0 / G1 phase, and have obvious induction of apoptosis. Inactivates the ubiquitous Abelson tyrosine kinase (Abl). [0003] At present, there is no literature report on other functions of imatinib mesylate. Contents of the invention [0004] The object of the present invention is to provide the application of imatinib mesylate (STI571) in the preparation of medicines for treating neurodegenerative diseases. [0005] In the application of imatinib mesylate provided by...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/506A61P25/16A61P25/28A61P25/00
Inventor 袁增强陈冬梅胡鹏马钧吴荣
Owner INSITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap